Physician profile
Alix Gilbert
NPI 1629374814
$2,860.49
in general payments reported to CMS, 2019-2025
37 companies · $861 in 2025
The $861 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $228 · 2022: $794 · 2023: $647 · 2024: $332 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,838.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $357.67 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $204.06 | 2022-2025 | Opdivo, Opdualag |
| Myriad Genetic Laboratories, INC. | $201.44 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $185.10 | 2023-2025 | |
| Daiichi Sankyo INC. | $160.32 | 2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $130.18 | 2022-2025 | Lynparza, Enhertu |
| Neurocrine Biosciences, INC. | $125.18 | 2023 | Ingrezza |
| Janssen Biotech, INC. | $119.45 | 2022-2025 | Darzalex, Carvykti, Tecvayli |
| Sobi, INC | $117.56 | 2022-2025 | |
| Astellas Pharma US INC | $116.40 | 2021-2025 | Vyloy |
| Puma Biotechnology, INC. | $115.24 | 2022 | |
| Novocure INC. | $102.54 | 2022 | |
| Incyte Corporation | $89.84 | 2022-2023 | Monjuvi, Jakafi |
| Gilead Sciences, INC. | $81.53 | 2023-2025 | Trodelvy |
| Pfizer INC. | $68.27 | 2023-2025 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alix Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.